Janiczek Wealth Management LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,972 shares of the biopharmaceutical company’s stock after selling 1,553 shares during the period. Janiczek Wealth Management LLC’s holdings in Pfizer were worth $439,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in PFE. Moneta Group Investment Advisors LLC grew its holdings in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after acquiring an additional 160,963,976 shares in the last quarter. Norges Bank bought a new position in Pfizer in the 4th quarter valued at $3,150,472,000. Wellington Management Group LLP increased its position in shares of Pfizer by 9.8% during the 1st quarter. Wellington Management Group LLP now owns 218,931,933 shares of the biopharmaceutical company’s stock valued at $8,932,423,000 after purchasing an additional 19,602,359 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Pfizer by 1,034.0% during the 1st quarter. Renaissance Technologies LLC now owns 12,149,955 shares of the biopharmaceutical company’s stock worth $495,718,000 after purchasing an additional 11,078,514 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Pfizer by 14.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 83,901,181 shares of the biopharmaceutical company’s stock worth $3,408,836,000 after buying an additional 10,560,702 shares during the last quarter. 68.05% of the stock is owned by institutional investors.
Pfizer Stock Performance
NYSE:PFE opened at $33.64 on Tuesday. The stock has a market cap of $189.93 billion, a P/E ratio of 8.95, a PEG ratio of 1.14 and a beta of 0.59. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. The business’s 50-day moving average price is $35.80 and its two-hundred day moving average price is $37.96. Pfizer Inc. has a twelve month low of $33.44 and a twelve month high of $54.93.
Pfizer Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th were given a dividend of $0.41 per share. The ex-dividend date was Thursday, July 27th. This represents a $1.64 dividend on an annualized basis and a yield of 4.88%. Pfizer’s payout ratio is 43.62%.
Wall Street Analyst Weigh In
Several brokerages have commented on PFE. HSBC began coverage on shares of Pfizer in a research report on Friday, July 14th. They issued a “buy” rating and a $50.00 price objective on the stock. Jefferies Financial Group reduced their price objective on Pfizer from $40.00 to $38.00 in a report on Wednesday, August 2nd. Morgan Stanley lowered their target price on Pfizer from $42.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 2nd. JPMorgan Chase & Co. cut their price target on Pfizer from $45.00 to $41.00 and set a “neutral” rating for the company in a research note on Monday, July 17th. Finally, StockNews.com started coverage on Pfizer in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. Twelve analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $46.35.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
- Five stocks we like better than Pfizer
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- Why Invest in High-Yield Dividend Stocks?
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Where to Find Earnings Call Transcripts
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.